111 related articles for article (PubMed ID: 9192201)
21. Industry perspectives on ICH guidelines.
Rockhold FW
Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
[TBL] [Abstract][Full Text] [Related]
22. A drug company report: what is the same and what is changing with respect to inclusion/exclusion of women in clinical trials.
Goldmann BJ
Food Drug Law J; 1993; 48(2):169-74. PubMed ID: 11653139
[No Abstract] [Full Text] [Related]
23. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
24. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
[TBL] [Abstract][Full Text] [Related]
25. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
26. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
27. Food and Drug Administration proposed testing guidelines for developmental toxicity studies. Revision Committee. FDA Guidelines for Developmental Toxicity and Reproduction, Food and Drug Administration.
Collins TF; Sprando RL; Shackelford ME; Hansen DK; Welsh JJ
Regul Toxicol Pharmacol; 1999 Aug; 30(1):39-44. PubMed ID: 10464045
[TBL] [Abstract][Full Text] [Related]
28. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
Honig PK
Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
[TBL] [Abstract][Full Text] [Related]
29. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
30. Population policies and the ideology of population control in India.
Nair S
Issues Reprod Genet Eng; 1992; 5(3):237-52. PubMed ID: 11651476
[No Abstract] [Full Text] [Related]
31. Reproductive choice in Islam: gender and state in Iran and Tunisia.
Obermeyer CM
Stud Fam Plann; 1994; 25(1):41-51. PubMed ID: 8209394
[TBL] [Abstract][Full Text] [Related]
32. The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions.
Bujar M; McAuslane N; Liberti L
Pharmaceut Med; 2021 Mar; 35(2):113-122. PubMed ID: 33537899
[TBL] [Abstract][Full Text] [Related]
33. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
Timmerman P; Anders Kall M; Gordon B; Laakso S; Freisleben A; Hucker R
Bioanalysis; 2010 Jul; 2(7):1185-94. PubMed ID: 21083233
[TBL] [Abstract][Full Text] [Related]
34. Regulatory acceptance and use of the Extended One Generation Reproductive Toxicity Study within Europe.
Schiffelers MJ; Blaauboer BJ; Bakker WE; Hendriksen CF; Krul C
Regul Toxicol Pharmacol; 2015 Feb; 71(1):114-24. PubMed ID: 25445002
[TBL] [Abstract][Full Text] [Related]
35. Standard protocols based on the ICH guidelines for reproductive and developmental toxicity studies: an international implementation.
Horimoto M
J Toxicol Sci; 1996 Dec; 21(5):451-5. PubMed ID: 9035052
[No Abstract] [Full Text] [Related]
36. Sensitivity of different generations and developmental stages in studies on reproductive toxicity.
Schulz F; Batke M; Mangelsdorf I; Pohlenz-Michel C; Simetska N; Lewin G
Toxicol Lett; 2014 Apr; 226(2):245-55. PubMed ID: 24525464
[TBL] [Abstract][Full Text] [Related]
37. Delays in new drug applications in Japan and industrial R&D strategies.
Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
[TBL] [Abstract][Full Text] [Related]
38. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE
Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
[TBL] [Abstract][Full Text] [Related]
39. The baby or the drug?
Rubin R
US News World Rep; 1995 Mar; 118(12):59-61. PubMed ID: 11645295
[No Abstract] [Full Text] [Related]
40. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
Milton MN; Horvath CJ
Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
